For its second fiscal quarter (ending June 30), IDEXX Laboratories Inc (NASDAQ: IDXX) has reported a -9% decline in E.P.S. from $2.70 a year ago to $2.46 in the current quarter. This result fell short of the consensus estimate of $2.87 by $-0.41. For the latest four quarters through June 30, E.P.S. were $10.19 versus $9.53 for the same period a year ago — an increase of 7%.
Recent Price Action
On 8/6/24, IDEXX Laboratories Inc (NASDAQ: IDXX) stock enjoyed a large increase of 3.1%, closing at $469.37. Moreover, trading volume in this advance was unusually high at 199% of normal. Relative to the market the stock has been weak over the last nine months and has declined -0.7% during the last week.
Current PriceTarget Research Rating
IDXX is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
IDEXX Laboratories has a current Value Trend Rating of D (Negative). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. IDEXX Laboratories has a poor Power Rating of 27 and a poor Appreciation Score of 26, with the Negative Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment